Pharmacologic Management of Refractory Chronic Pain and Depression in Hypermobility Disorders

Medication Optimization

In patients with hypermobile Ehlers‑Danlos syndrome, start duloxetine at 30 mg once daily for the first week, then titrate to 60 mg once daily; this gradual initiation reduces early nausea, which is especially important in those with comorbid functional gastrointestinal disorders. 6

The 2025 American Gastroenterological Association (AGA) guidelines list duloxetine, an SNRI, as a first‑line neuromodulator for chronic abdominal and musculoskeletal pain in hEDS/hypermobility spectrum disorders. 6
Duloxetine targets both neuropathic pain components and co‑existing depression/anxiety, conditions that affect the vast majority of hEDS patients (≈ 98 % meet criteria for disorders of gut‑brain interaction). 6

Because duloxetine can cause modest systolic/diastolic blood‑pressure elevation and increased heart rate, clinicians should measure blood pressure and pulse at every follow‑up visit, with particular vigilance during the first few weeks; this is critical given the high prevalence of postural orthostatic tachycardia syndrome (POTS) in hEDS. 7

Opioids are contraindicated for chronic pain in hEDS; they are associated with worsened gastrointestinal symptoms, higher complication rates, and poorer long‑term outcomes. The 2025 AGA guidelines explicitly recommend avoiding or discontinuing opioids in this population. 6
Non‑steroidal anti‑inflammatory drugs (NSAIDs) should be avoided, as they exacerbate gastrointestinal symptoms and can trigger mast‑cell degranulation in hEDS patients. 7

A low‑dose tricyclic antidepressant (amitriptyline 10–75 mg at bedtime) is recommended by the AGA as an alternative neuromodulator for neuropathic pain and comorbid insomnia in hEDS, with careful titration to mitigate anticholinergic effects. 6

Concurrent brain‑gut behavioral therapies (e.g., cognitive‑behavioral therapy or acceptance and commitment therapy) should be incorporated, as psychological factors such as pain catastrophizing and activity avoidance significantly influence pain chronicity and disability in hEDS. 6
Systematic screening and treatment of common comorbidities—including POTS (via active‑stand vital signs), mast‑cell activation syndrome (using antihistamines and mast‑cell stabilizers), and functional gastrointestinal disorders—are essential because these conditions are highly prevalent in hEDS and amplify pain. [6][7]